Diginex Taps New Marketing Chief to Unify Brand as It Races Against Nasdaq Deadline and $150M Deal Uncertainty

Diginex launches Risk-to-Remedy platform amid stock slide to $0.97, appoints new CMO and CIO to integrate acquisitions, faces Nasdaq compliance deadline.

The contradiction at the heart of Diginex is getting harder to ignore. The London-based ESG technology company launched its “Risk-to-Remedy” compliance platform in early June, tapping into a regulatory wave that is reshaping global supply chains. Yet its Nasdaq-listed shares ended the same week at $0.97, down nearly 20% over the past month, with a relative strength index of 29.8 deep in oversold territory. The market is either ignoring a structural tailwind or pricing in execution risks that remain unresolved.

Against that backdrop, Diginex has moved to strengthen its leadership team. On 10 June, the company appointed Carole Zibi as its new Chief Marketing Officer. Her mandate is to forge a single brand identity from Diginex and its three recent acquisitions — Plan A.Earth, Matter DK and The Remedy Project — which have been operating as separate units since a unified strategy was adopted in March. Zibi had been Vice President of Marketing at Plan A since November 2023, before Diginex took over the company in January. Her prior experience includes building European markets for Disney, Yahoo!, Vogue and LinkedIn, where she opened the French office and later led marketing for Talent Solutions across Europe, the Middle East and Africa.

At the same time, Diginex named Archana Kotecha, founder of The Remedy Project, as Chief Impact Officer. She is tasked with linking measurable customer outcomes and revenue growth by combining sustainability and compliance solutions. The appointments are part of a broader push to integrate the group’s four operating entities into a single technology platform covering carbon accounting, sustainability reporting, human rights due diligence and supply chain transparency.

That consolidation is happening under the shadow of a Nasdaq compliance notice. In March, the exchange warned that Diginex’s stock had closed below $1.00 for 30 consecutive trading days, violating Listing Rule 5550(a)(2). The company has until 21 September to regain compliance. It executed an 8-for-1 reverse share split in April, reducing outstanding shares from roughly 233 million to about 29 million. On 11 June, the stock traded in a range of $0.96 to $1.09 — still dangerously close to the threshold.

The regulatory environment, however, provides a powerful narrative for growth. The global market for supply chain due diligence was estimated at $3.8 billion in 2025 and is projected to reach $9.6 billion by 2034, driven by tightening rules in Europe, the UK, Australia and Canada. Frameworks such as the UK Modern Slavery Act, the Australian Modern Slavery Act, the Canadian Fighting Against Forced Labour Act, the EU’s CSDDD, Germany’s supply chain due diligence law and the EU Forced Labour Regulation are forcing companies to produce verifiable evidence that they are not benefiting from exploitation.

Diginex’s new Risk-to-Remedy platform is designed to bridge a specific gap: companies can already map suppliers and assess risks, but regulators and civil society increasingly demand proof that remediation actually happens. The platform combines LUMEN for risk assessment, APPRISE for direct worker engagement and The Remedy Project’s expertise in corrective action, creating a single framework that integrates worker-level evidence, prioritised actions and regulator-ready reports.

What currently dominates the stock’s direction, though, is not the product roadmap but the pending acquisition of Resulticks. The transaction — whose closing deadline fell on 12 June — remains subject to the satisfaction or waiver of closing conditions, and Diginex has stressed there is no guarantee of completion. The potential prize is significant: Resulticks is expected to contribute approximately $150 million in annual revenue and between $46 million and $50 million in EBITDA. If closed, the deal would extend Diginex from sustainability data into real-time decision-making and customer engagement.

For now, the market is treating the stock as a binary bet. Diginex’s market capitalisation stands at roughly €26 million, with annualised volatility of 126%. The RSI of 29.8 suggests sellers remain in control as long as the Resulticks deal hangs in the balance and Risk-to-Remedy has yet to generate the revenues that would justify a higher valuation. The regulatory wave is real; the execution is the open question.